Your browser doesn't support javascript.
loading
New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.
Pavlos, Rebecca; Deshpande, Pooja; Chopra, Abha; Leary, Shay; Strautins, Kaija; Nolan, David; Thorborn, Daren; Shaefer, Mark; Rauch, Andri; Dunn, David; Montaner, Julio; Rachlis, Anita; Almeida, Coral-Ann; Choo, Linda; James, Ian; Redwood, Alec J; Li, Yueran; Gaudieri, Silvana; Mallal, Simon A; Phillips, Elizabeth J.
Afiliación
  • Pavlos R; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; Telethon Kids Institute, Western Australia, Australia.
  • Deshpande P; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; School of Human Sciences, University of Western Australia, Western Australia, Australia.
  • Chopra A; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
  • Leary S; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
  • Strautins K; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
  • Nolan D; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; Department of Clinical Immunology, Royal Perth Hospital, Western Australia, Australia.
  • Thorborn D; Celgene Corporation, NJ, USA.
  • Shaefer M; ViiV Healthcare at Research Triangle Park, NC, USA.
  • Rauch A; Inselspital, Bern, Switzerland.
  • Dunn D; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
  • Montaner J; British Columbia Centre for Excellence in HIV/AIDS, Vancouver British Columbia, Canada.
  • Rachlis A; Sunnybrook Health Sciences Centre, Toronto, Canada; University of Toronto,Toronto, Canada.
  • Almeida CA; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; Department of Haematology, Fiona Stanley Hospital, Western Australia, Australia.
  • Choo L; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
  • James I; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
  • Redwood AJ; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; Institute for Respiratory Health, University of Western Australia, Western Australia, Australia.
  • Li Y; School of Human Sciences, University of Western Australia, Western Australia, Australia.
  • Gaudieri S; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; School of Human Sciences, University of Western Australia, Western Australia, Australia; Vanderbilt University Medical Centre, Nashville, USA.
  • Mallal SA; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; Vanderbilt University Medical Centre, Nashville, USA.
  • Phillips EJ; Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia; Vanderbilt University Medical Centre, Nashville, USA. Electronic address: elizabeth.j.phillips@vumc.org.
Hum Immunol ; 81(6): 300-304, 2020 Jun.
Article en En | MEDLINE | ID: mdl-32173028
Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS. However, 45% of individuals who carry HLA-B*57:01 can tolerate ABC. We investigated immune and non-immune related genes in ABC HSS (n = 95) and ABC tolerant (n = 43) HLA-B*57:01 + patients to determine other factors required for the development of ABC HSS. Assignment of phenotype showed that ABC HSS subjects were significantly less likely than tolerants to carry only ERAP1 hypoactive trimming allotypes (p = 0.02). An altered self-peptide repertoire model by which abacavir activates T cells is in keeping with observation that endoplasmic reticulum aminopeptidase 1 (ERAP1) allotypes that favour efficient peptide trimming are more common in ABC HSS patients compared to patients who tolerate ABC. Independently, non-specific immune activation via soluble cluster of differentiation antigen 14 (sCD14) may also influence susceptibility to ABC HSS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Didesoxinucleósidos / Antígenos HLA-B / Infecciones por VIH / VIH-1 / Fármacos Anti-VIH / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Síndrome de Hipersensibilidad a Medicamentos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Hum Immunol Año: 2020 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Didesoxinucleósidos / Antígenos HLA-B / Infecciones por VIH / VIH-1 / Fármacos Anti-VIH / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Síndrome de Hipersensibilidad a Medicamentos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Hum Immunol Año: 2020 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos